Advertisement

Neue Aspekte in der Behandlung des fortgeschrittenen Prostatakarzinoms

  • N. T. Schmeller

Zusammenfassung

Seit der Einführung der kontrasexuellen Therapie durch Huggins und Hodges hat sich die Prognose des metastasierten Prostatakarzinoms nicht wesentlich geändert. Ob diese Standardtherapie überhaupt zu einer Verlängerung der Überlebenszeit führt, ist umstritten. So verglichen Lepor et al. die Überlebenszeit von 75 Patienten, die zwischen 1937 und 1940 behandelt wurden mit der Überlebenszeit von 52 Patienten zwischen 1942 und 1944, also nach Einführung der hormonellen Therapie. Die statistische Analyse zeigte keinen signifikanten Einfluß der Hormontherapie auf die Überlebenszeit bei dieser insgesamt jedoch sicher heterogenen Patientengruppe [12].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Bauer HW, Schmeller NT, Schmiedt E (1985) Aminoglutethimid zur Behandlung des fortge-schrittenen Prostatakarzinoms. Urologe (A) 24: 46–48Google Scholar
  2. 2.
    Bulbul MA, Huben RP, Murphy GP (1986) Interferon-beta treatment of metastatic prostate cancer. J Surg Oncol 33: 231–233PubMedCrossRefGoogle Scholar
  3. 3.
    Burton S, Trachtenberg J (1986) Effectiveness of antiandrogens in the rat. J Urol 136: 932–935PubMedGoogle Scholar
  4. 4.
    Chang AY, Fisher HA, Spiers AS, Boros L (1986) Toxicities of human recombinant interferon alpha 2 in patients with advanced prostate carcinoma. J Interferon Res 6: 713–715PubMedCrossRefGoogle Scholar
  5. 5.
    Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA et al. (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419–424PubMedCrossRefGoogle Scholar
  6. 6.
    De Kernion JN, Murphy GP, Priore R (1988) Comparison of flutamide and emcyt in hor-mone-refractory metastatic prostatic cancer. Urology 31: 312–317PubMedCrossRefGoogle Scholar
  7. 7.
    Ebert T, Steinfeld J, Bander NH (1989) Modulation von HLA-Antigenen beim Nierenzellkarzinom. 34. Kongreß der Deutschen Gesellschaft für Urologie e.V., Freiburg, 4.–7.10.1989. Urologe (A, Suppl): A 10Google Scholar
  8. 8.
    Fowler JE, Whitmore WF (1981) The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 126: 372–375PubMedGoogle Scholar
  9. 9.
    Geller J (1985) Rationale for blockade of adrenal as well as testicular androgens in the treat¬ment of advanced prostate cancer. Semin Oncol (Suppl. 1 ) 12: 28–35Google Scholar
  10. 10.
    Johansson J-E, Andersson S-O, Beckman K-W, Lingardh G, Zador G (1987) Clinical evaluation of flutamide and estramustine as initial treatment of metastatic carcinoma of prostate. Urology 24: 55–59CrossRefGoogle Scholar
  11. 11.
    Labrie F, Dupont A, Cusan L, Giguere M, Bergeron N, Borsanyi P, Lacourciere Y et al. (1988) Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today’s therapy of choice. J Steroid Biochem 30: 107–117PubMedCrossRefGoogle Scholar
  12. 12.
    Lepor H, Ross A, Walsh PC (1982) The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol 128: 335–340PubMedGoogle Scholar
  13. 13.
    Lund F, Rasmussen F (1988) Flutamide versus stilboestrol in the management of advanced prostatic cancer. Br J Urol 61: 140–142PubMedCrossRefGoogle Scholar
  14. 14.
    Medenica R, Slack N (1985) Clinical results of leucocyte interferon-induced tumor regression in resistant human metastatic cancer resistant to chemotherapy and/or radiotherapy-pulse therapy schedule. Cancer Drug Deliv 2: 53–76PubMedCrossRefGoogle Scholar
  15. 15.
    Neri R, Kassem N (1984) Biological and clinical properties of antiandrogens. In: Bresciani F, King RJB, Lippmann ME, Namer M, Raynaud J-P (eds) Progress in cancer research and therapy, vol 31. Raven Press, New York, pp 507–518Google Scholar
  16. 16.
    Pavone-Macaluso M, DeVoogt HJ, Viggiano G, Barasolo E, Lardennois B, Be Pauw M, Sylvester R (1986) Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogester- one acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 136:624–631PubMedGoogle Scholar
  17. 17.
    Sica G, Fabbroni L, Castaghetta L, Cacciatore M, Pavone-Macaloso M (1989) Antiproliferative effect of interferons on human prostate carcinoma cell lines. Urol Res 17: 111–115PubMedCrossRefGoogle Scholar
  18. 18.
    Sica G, Fabbroni L, Del’Aqua S, Cacciatore M, Pavone-Macaluso M (1989) Interferon and hormone-sensitivity in prostatic cancer cells. 7th Congress of the European Society for Urologie Oncology and Endocrinology, Düsseldorf, 26.–28. 10. 1989Google Scholar
  19. 19.
    Trachtenberg J, Beland G, Elhilali MM, Fradet Y, Laroche B, Ramsey EW, Venner PN (1989) A randomised trial of total androgen ablation vrs. orchiectomy in patients with metastatic prostatic cancer. J Urol 141: 347AGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • N. T. Schmeller
    • 1
  1. 1.Klinikum GroßhadernUrologische Klinik und Poliklinik der LMUMünchen 70Germany

Personalised recommendations